- Home
- QRVO vs IONS Comparison
QRVO vs IONS Comparison
Compare QRVO & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QRVO
- IONS
- Stock Information
- Founded
- QRVO 1957
- IONS 1989
- Country
- QRVO United States
- IONS United States
- Employees
- QRVO N/A
- IONS N/A
- Industry
- QRVO Semiconductors
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- QRVO Technology
- IONS Health Care
- Exchange
- QRVO Nasdaq
- IONS Nasdaq
- Market Cap
- QRVO 6.3B
- IONS 6.0B
- IPO Year
- QRVO 1997
- IONS 1991
- Fundamental
- Price
- QRVO $70.85
- IONS $36.17
- Analyst Decision
- QRVO Hold
- IONS Buy
- Analyst Count
- QRVO 18
- IONS 18
- Target Price
- QRVO $96.31
- IONS $62.00
- AVG Volume (30 Days)
- QRVO 3.4M
- IONS 1.7M
- Earning Date
- QRVO 01-29-2025
- IONS 02-19-2025
- Dividend Yield
- QRVO N/A
- IONS N/A
- EPS Growth
- QRVO N/A
- IONS N/A
- EPS
- QRVO N/A
- IONS N/A
- Revenue
- QRVO $3,948,029,000.00
- IONS $803,067,000.00
- Revenue This Year
- QRVO N/A
- IONS N/A
- Revenue Next Year
- QRVO $4.55
- IONS $19.61
- P/E Ratio
- QRVO N/A
- IONS N/A
- Revenue Growth
- QRVO 26.11
- IONS 30.57
- 52 Week Low
- QRVO $64.54
- IONS $33.33
- 52 Week High
- QRVO $130.99
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- QRVO 47.96
- IONS 41.84
- Support Level
- QRVO $68.10
- IONS $36.39
- Resistance Level
- QRVO $70.84
- IONS $38.90
- Average True Range (ATR)
- QRVO 2.31
- IONS 1.52
- MACD
- QRVO 0.85
- IONS -0.08
- Stochastic Oscillator
- QRVO 87.28
- IONS 6.61
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.